Andrea Dalbeni
Verona, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 112 publications
Author's reply: ``Survival fragility in advanced hepatocellular carcinoma immunotherapy trials requires clinical context''.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 13, 2026
Statins in chronic liver disease and its complications: An umbrella review and meta-analysis of systematic reviews.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: March 30, 2026
Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 13, 2026
Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: January 16, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 28, 2025
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study.
Journal: Hepatology (Baltimore, Md.)
Published: November 22, 2025
Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study.
Journal: Diabetes, obesity & metabolism
Published: September 05, 2025
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: September 04, 2025
Response to: "The Role of Platelets in MASLD: From Mechanisms to Clinical Implications".
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 06, 2025
Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework.
Journal: Cancer medicine
Published: July 24, 2025
Last Updated: 09/26/2026